A blueprint for new drugs

A new tool could point researchers to more effective pharmaceuticals and more environment friendly agrichemicals. The tool highlights possible molecular targets in genomic data, according to scientists at the Blueprint Initiative, a research program led by Christopher Hogue of Canada's Mount Sinai Hospital's Samuel Lunenfeld Research Institute. SMID-Genomes is a binding annotation and comparison tool that focuses on the interactions of small molecules and targets in the body involved with disease. It provides useful information that could shorten lead development times in the search for antimicrobial drugs. SMID-Genomes could also provide new insights into the interaction between small molecules and pest and weed proteins and so allow chemists to develop more specific and so safer pesticides and herbicides.